doi:10.3969/j.issn.1004-583X.2022.09.018

Abstract

CLC Number:

R692

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.09.018

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I9/855

References 42

[1]	Roux-Marson C, Baranski JB, Fafin C, et al. Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease[J]. BMC Geriatr, 2020, 20(1): 87. doi: 10.1186/s12877-020-1485-4 pmid: 32131742
[2]	Sun L, Tan X, Cao X, et al. Assessed value of high-sensitivity cardiac troponin T for cardiovascular disease among CKD patients[J]. Ren Fail, 2016, 38(5): 728-737. doi: 10.3109/0886022X.2016.1158040 pmid: 26984066
[3]	Wettersten N, Maisel AS. Biomarker developments in heart failure: 2016 and beyond[J]. Curr Opin Cardiol, 2019, 34(2): 218-224. doi: 10.1097/HCO.0000000000000596 pmid: 30633074
[4]	Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review[J]. JAMA, 2019, 322(13): 1294-1304. doi: 10.1001/jama.2019.14745 pmid: 31573641
[5]	Murton M, Goff-Leggett D, Bobrowska A, et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: A systematic review[J]. Adv Ther, 2021, 38(1): 180-200. doi: 10.1007/s12325-020-01568-8 pmid: 33231861
[6]	Tuegel C, Bansal N. Heart failure in patients with kidney disease[J]. Heart, 2017, 103(23): 1848-1853. doi: 10.1136/heartjnl-2016-310794 pmid: 28716974
[7]	Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: Epidemiology, mechanisms and management[J]. Nat Rev Nephrol, 2016, 12(10): 610-623. doi: 10.1038/nrneph.2016.113 pmid: 27573728
[8]	Wang K, Zelnick LR, Anderson A, et al. Cardiac biomarkers and risk of mortality in CKD (the CRIC Study)[J]. Kidney Int Rep, 2020, 5(11): 2002-2012. doi: 10.1016/j.ekir.2020.08.028 pmid: 33163721
[9]	宋昊岚, 杨婷婷, 李贵星. N末端脑利钠肽前体(NT-proBNP)在评估慢性肾脏疾病患者心功能中的价值[J]. 四川大学学报(医学版), 2017, 48(4): 561-565.
[10]	李俐, 肖俊会, 毕健成, 等. 老年慢性心力衰竭患者血浆BNP、TNF-α和血清cTnI水平与心室重构指标及心功能的相关性[J]. 中国老年学杂志, 2019, 39(5): 1031-1034.
[11]	Bansal N, Zelnick LR, Soliman EZ, et al. Change in cardiac biomarkers and risk of incident heart failure and atrial fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) study[J]. Am J Kidney Dis, 2021, 77(6): 907-919. doi: 10.1053/j.ajkd.2020.09.021 URL
[12]	Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship[J]. Eur J Clin Invest, 2014, 44(3): 303-308. doi: 10.1111/eci.12234 pmid: 24372567
[13]	Jafri L, Kashif W, Tai J, et al. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: Selecting the optimal heart failure marker in patients with impaired kidney function[J]. BMC Nephrol, 2013, 14: 117. doi: 10.1186/1471-2369-14-117 pmid: 23725445
[14]	Mueller C, Mcdonald K, De Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations[J]. Eur J Heart Fail, 2019, 21(6): 715-731. doi: 10.1002/ejhf.1494 pmid: 31222929
[15]	Januzzi J, Chen-Tournoux A, Christenson R, et al. N-terminal pro-B-type natriuretic peptide in the emergency department: The ICON-RELOADED study[J]. J Am Coll Cardiol, 2018, 71(11): 1191-1200. doi: S0735-1097(18)30166-9 pmid: 29544601
[16]	Gaggin HK, Januzzi JL. Biomarkers and diagnostics in heart failure[J]. Biochim Biophys Acta, 2013, 1832(12): 2442-2450. doi: 10.1016/j.bbadis.2012.12.014 pmid: 23313577
[17]	Plawecki M, Morena M, Kuster N, et al. sST2 as a new biomarker of chronic kidney disease-induced cardiac remodeling: Impact on risk prediction[J]. Mediators Inflamm, 2018, 2018: 3952526.
[18]	汤丰宁, 龙勇, 丁宁, 等. sST2、IL-33与慢性肾衰竭患者心力衰竭的相关性研究[J]. 中国医学前沿杂志(电子版), 2019, 11(4): 44-48.
[19]	Mirna M, Topf A, Wernly B, et al. Novel biomarkers in patients with chronic kidney disease: An analysis of patients enrolled in the GCKD-study[J]. J Clin Med, 2020, 9(3):886. doi: 10.3390/jcm9030886 URL
[20]	Benes J, Kotrc M, Wohlfahrt P, et al. The role of GDF-15 in heart failure patients with chronic kidney disease[J]. Can J Cardiol, 2019, 35(4): 462-470. doi: S0828-282X(18)31389-8 pmid: 30935637
[21]	Stein NR, Zelnick LR, Anderson AH, et al. Associations between cardiac biomarkers and cardiac structure and function in CKD[J]. Kidney Int Rep, 2020, 5(7): 1052-1060. doi: 10.1016/j.ekir.2020.04.031 pmid: 32647762
[22]	Tummalapalli SL, Zelnick LR, Andersen AH, et al. Association of cardiac biomarkers with the Kansas City Cardiomyopathy Questionnaire in patients with chronic kidney disease without heart failure[J]. J Am Heart Assoc, 2020, 9(13): e014385. doi: 10.1161/JAHA.119.014385 URL
[23]	Bayes-Genis A, Zamora E, De Antonio M, et al. Soluble ST2 serum concentration and renal function in heart failure[J]. J Card Fail, 2013, 19(11): 768-775. doi: 10.1016/j.cardfail.2013.09.005 pmid: 24263122
[24]	Desmedt V, Desmedt S, Delanghe JR, et al. Galectin-3 in renal pathology: More than just an innocent bystander[J]. Am J Nephrol, 2016, 43(5): 305-317. doi: 10.1159/000446376 pmid: 27166158
[25]	班爱军, 赵云程, 郝耀辉, 等. 慢性肾脏病患者循环半乳糖凝集素3和N端前脑钠肽水平与心力衰竭的关系[J]. 微循环学杂志, 2017, 27(4): 51-55.
[26]	Myhre PL, Claggett B, Ballantyne CM, et al. Association between circulating troponin concentrations, left ventricular systolic and diastolic functions, and incident heart failure in older adults[J]. JAMA Cardiol, 2019, 4(10): 997-1006. doi: 10.1001/jamacardio.2019.3113 pmid: 31483438
[27]	Mishra RK, Li Y, Ricardo AC, et al. Association of N-terminal pro-B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC])[J]. Am J Cardiol, 2013, 111(3): 432-438. doi: 10.1016/j.amjcard.2012.10.019 pmid: 23178053
[28]	Colbert G, Jain N, de Lemos JA, et al. Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD[J]. Clin J Am Soc Nephrol, 2015, 10(3): 515-529. doi: 10.2215/CJN.03600414 URL
[29]	Chotivanawan T, Krittayaphong R. Normal range of serum highly-sensitive troponin-T in patients with chronic kidney disease stage 3-5[J]. J Med Assoc Thai, 2012, 95(Suppl 2) :S127-S132.
[30]	Hasegawa M, Ishii J, Kitagawa F, et al. Plasma neutrophil gelatinase-associated lipocalin as a predictor of cardiovascular events in patients with chronic kidney disease[J]. Biomed Res Int, 2016, 2016: 8761475.
[31]	Park M, Hsu CY, Go AS, et al. Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death: The CRIC study[J]. Clin J Am Soc Nephrol, 2017, 12(5): 761-771. doi: 10.2215/CJN.08560816 URL
[32]	Huerta A, López B, Ravassa S, et al. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: Potential role of altered collagen metabolism[J]. J Hypertens, 2016, 34(1): 130-138. doi: 10.1097/HJH.0000000000000757 pmid: 26575701
[33]	宋培. 3种血清标志物在尿毒症合并心力衰竭诊断中的应用价值[J]. 国际检验医学杂志, 2019, 40(20): 2475-2478.
[34]	Tedeschi A, Agostoni P, Pezzuto B, et al. Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid[J]. Eur J Prev Cardiol, 2020, 27(2_suppl): 35-45. doi: 10.1177/2047487320957793 pmid: 33238740
[35]	Kube J, Ebner N, Jankowska E A, et al. The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure[J]. Int J Cardiol, 2016, 219: 84-91. doi: 10.1016/j.ijcard.2016.05.006 pmid: 27288971
[36]	Li J, Cui Y, Huang A, et al. Additional diagnostic value of growth differentiation factor-15 (GDF-15) to N-terminal B-type natriuretic peptide (NT-proBNP) in patients with different stages of heart failure[J]. Med Sci Monit, 2018, 24: 4992-4999. doi: 10.12659/MSM.910671 URL
[37]	Gergei I, Krämer BK, Scharnagl H, et al. Renal function, N-terminal pro-B-type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction[J]. Peptides, 2019, 111: 112-117. doi: S0196-9781(18)30071-8 pmid: 29684593
[38]	蒋桂珍, 章丽娟, 周雪芬. NT-proBNP联合红细胞分布宽度预测老年慢性心力衰竭合并Ⅱ型心肾综合征的临床价值[J]. 心脑血管病防治, 2020, 20(4): 375-379.
[39]	Plawecki M, Morena M, Kuster N, et al. sST2 as a new biomarker of chronic kidney disease-induced cardiac remodeling: Impact on risk prediction[J]. Mediators Inflamm, 2018, 2018: 3952526.
[40]	胡俊恒, 黄志敏, 冯玉婵. 血清CK-MB、BNP、Scr联合检测对尿毒症患者心衰的诊断价值探究[J]. 中国医学创新, 2020, 17(16): 115-118.
[41]	王精文, 张欢, 赵冠杰, 等. NT-pro BNP联合Cys-C评估慢性肾脏病患者心功能的价值[J]. 中国实验诊断学, 2020, 24(10): 1598-1601.
[42]	吴锡信, 洪明, 胡蓉. N末端B型脑钠肽前体与血清肌酐、胱抑素C比值对慢性肾脏病并心力衰竭的诊断价值[J]. 国际医药卫生导报, 2015, 21(14): 1989-1991, 2004.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 42

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(2): 183-187.
[2]	Yang Xingmeng, Ma Xiaoying, Sheng Yuping, Liu Ye, Zhang Haoran, Xu Haiping, Wang Na, Sun Fuyun. Correlation between homocysteine and abdominal aortic calcification in non-dialysis patients with stage 5 chronic kidney disease [J]. Clinical Focus, 2024, 39(1): 30-33.
[3]	Dong Hui, Huang Wenhui, Zhao Hui, Qian Rui. Adult Bartter syndrome complicated with acute exacerbation of chronic renal insufficiency: A case report [J]. Clinical Focus, 2023, 38(11): 1022-1026.
[4]	Liu Yan, Liu Qiong, Liang Xiaomei, Liu Bing. Secondary infection of spontaneous perirenal hemorrhage with fever as the main symptom: A case report and literature review [J]. Clinical Focus, 2023, 38(9): 823-826.
[5]	Wang Tao, Gao Yuwei, Wang Xinghua, Hu Xiuhong, Cui Hongrui, Xu Baozhen, Yang Hongjuan. Correlation of anti-phospholipase A2 receptor antibody with idiopathic membranous nephropathy [J]. Clinical Focus, 2023, 38(7): 606-612.
[6]	Gao Qinyu, Bao Beiyan, Jin Yan, Zhao Yu. Analysis of clinical features and prognostic factors of IgA nephropathy complicated with depression [J]. Clinical Focus, 2023, 38(6): 510-515.
[7]	Wang Lingling, Wu Jinlan, Wu Wei, Shen Shipeng, Chi Yanqing, Liu Maodong. A meta-analysis of the renal protective effects of vitamin D and its analogues in non dialysis patients with chronic kidney disease [J]. Clinical Focus, 2022, 37(12): 1081-1088.
[8]	Wang Pengrui, Chen Huaqian, Yang Tao, Zhao Li, Li Peng. The effect of serum intact parathyroid hormone level on the maturation of autogeneous arteriovenous fistula [J]. Clinical Focus, 2022, 37(12): 1094-1098.
[9]	Tong Tian, Wang Ruiying, Zhang Lihui, Liu Zhihong, Luo Jianqin, Zhao Zhansheng. Gitelman syndrome with normomagnesemia: A case report and literature review [J]. Clinical Focus, 2022, 37(11): 1031-1036.
[10]	. [J]. Clinical Focus, 2022, 37(11): 1053-1056.
[11]	Zhou Ren, Chen Yating, Zhang Yong. Efficacy and safety of Roxadustat on renal anemia in hemodialysis patients:A meta-analysis [J]. Clinical Focus, 2022, 37(4): 305-310.
[12]	Gao Pengli, Chen Lili, Tian Fen, Zhang Jiaqian, Chen Yipeng, Qi Xiaojing, Xing Guangqun. Impact of body mass index in the clinicopathology and prognosis of patients with IgA nephropathy [J]. Clinical Focus, 2022, 37(3): 234-242.
[13]	Li Yingying, Li Ting, Zhang Ming, Fan Minghua, Xing Guangqun. Monitoring significance of CD4⁺ T lymphocyte count on evaluating frailty status of chronic renal failure in patients [J]. Clinical Focus, 2022, 37(3): 243-247.
[14]	Li Wenzhe, Shang Jinchun, Li Chunmei, Tian Fen, Li Jun, Cui Li, Xing Guangqun. Risk factors of cerebral hemorrhage in uremic patients on regular hemodialysis [J]. Clinical Focus, 2022, 37(1): 20-25.
[15]	Tang Chunxia, Xue Yuxi, Wang Wei. Correlation between serum TGF-β1, IL-17 levels and prognosis of patients with acute pyelonephritis treated with cefotaxime sodium [J]. Clinical Focus, 2021, 36(12): 1106-1109.